Ginkgo Bioworks (DNA) Competitors $10.08 +1.34 (+15.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNA vs. RXRX, CNTA, APGE, IBRX, WVE, MIRM, AKRO, TARS, AMPH, and IRONShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Recursion Pharmaceuticals (RXRX), Centessa Pharmaceuticals (CNTA), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Recursion Pharmaceuticals Centessa Pharmaceuticals Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine Ginkgo Bioworks (NYSE:DNA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking. Which has higher valuation & earnings, DNA or RXRX? Recursion Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$217.11M2.67-$892.87M-$13.08-0.77Recursion Pharmaceuticals$64.60M26.76-$328.07M-$1.53-3.94 Is DNA or RXRX more profitable? Ginkgo Bioworks has a net margin of -298.78% compared to Recursion Pharmaceuticals' net margin of -579.52%. Ginkgo Bioworks' return on equity of -58.54% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-298.78% -58.54% -34.24% Recursion Pharmaceuticals -579.52%-76.56%-55.68% Does the media refer more to DNA or RXRX? In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 7 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.67 beat Recursion Pharmaceuticals' score of 0.41 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer DNA or RXRX? Recursion Pharmaceuticals received 4 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 56.00% of users gave Recursion Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Recursion PharmaceuticalsOutperform Votes2856.00% Underperform Votes2244.00% Do insiders and institutionals hold more shares of DNA or RXRX? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, DNA or RXRX? Ginkgo Bioworks has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do analysts prefer DNA or RXRX? Ginkgo Bioworks currently has a consensus target price of $4.58, indicating a potential downside of 54.61%. Recursion Pharmaceuticals has a consensus target price of $9.25, indicating a potential upside of 53.40%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryRecursion Pharmaceuticals beats Ginkgo Bioworks on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$579.39M$2.94B$5.13B$19.18BDividend YieldN/A1.90%4.93%3.60%P/E Ratio-0.7746.7389.7441.30Price / Sales2.67415.011,115.2917.60Price / CashN/A182.1042.8221.28Price / Book0.463.894.775.32Net Income-$892.87M-$42.21M$120.04M$989.88M7 Day Performance6.78%-2.15%-1.92%-3.54%1 Month Performance53.08%4.20%11.46%-3.68%1 Year PerformanceN/A18.39%30.52%12.14% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.5512 of 5 stars$10.08+15.3%$4.58-54.6%N/A$579.39M$217.11M-0.771,218Gap DownHigh Trading VolumeRXRXRecursion Pharmaceuticals2.4151 of 5 stars$7.51+8.1%$9.25+23.2%-36.3%$2.15B$44.58M-4.85400News CoverageHigh Trading VolumeCNTACentessa Pharmaceuticals2.9997 of 5 stars$16.29-1.7%$25.83+58.6%+131.0%$2.15B$6.85M-10.8372Insider TradeAPGEApogee Therapeutics2.5994 of 5 stars$46.76+5.1%$83.88+79.4%+92.5%$2.11BN/A-18.3991IBRXImmunityBio2.1332 of 5 stars$3.01+4.9%$17.38+477.2%-42.2%$2.10B$7.33M-3.36590Analyst ForecastWVEWave Life Sciences4.8841 of 5 stars$13.57+1.0%$22.22+63.8%+181.5%$2.07B$113.31M-12.11240MIRMMirum Pharmaceuticals4.0875 of 5 stars$42.51+0.2%$57.73+35.8%+34.8%$2.04B$307.03M-21.01140Positive NewsAKROAkero Therapeutics4.0824 of 5 stars$29.00+0.4%$46.83+61.5%+36.1%$2.02BN/A-7.7030Insider TradeTARSTarsus Pharmaceuticals0.3236 of 5 stars$51.39-2.1%$54.20+5.5%+164.4%$1.96B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8626 of 5 stars$40.83-3.3%$60.33+47.8%-33.1%$1.96B$644.40M14.081,761IRONDisc Medicine3.4713 of 5 stars$65.58+1.1%$87.50+33.4%+13.2%$1.95BN/A-16.3078Insider Trade Related Companies and Tools Related Companies Recursion Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Apogee Therapeutics Competitors ImmunityBio Competitors Wave Life Sciences Competitors Mirum Pharmaceuticals Competitors Akero Therapeutics Competitors Tarsus Pharmaceuticals Competitors Amphastar Pharmaceuticals Competitors Disc Medicine Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:DNA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
